Tasly Pharmaceutical Group Co., Ltd.

Tasly Pharmaceutical Group Co., Ltd. faced a decline in stock value amid ongoing challenges, including a 9.48% decrease in net sales over five years and a 55.59% drop in net profit for the latest quarter. The company continues to struggle against broader market performance.

Tasly Pharmaceutical Group Co., Ltd. has recently experienced a change in its evaluation, reflecting shifts in financial metrics such as P/E ratio and Price to Book Value. Despite some positive quarterly performance, the company faces challenges with declining net sales and operating profit over the past five years.

Tasly Pharmaceutical Group Co., Ltd. faced a significant decline in its stock today, contrasting with the modest gain of the China Shanghai Composite. Over the past year, Tasly has struggled with a notable drop in net profit and long-term growth challenges, reflecting broader difficulties in the pharmaceuticals sector.

Tasly Pharmaceutical Group Co., Ltd. experienced a notable intraday gain, contrasting with its longer-term performance, which shows a significant decline over the past year and year-to-date. The company faces challenges in net sales growth, despite holding a market capitalization of CNY 20,981 million and a dividend yield of 2.22%.

Tasly Pharmaceutical Group Co., Ltd. has recently experienced a change in its evaluation, reflecting adjustments in its financial metrics and market position. Key ratios indicate operational efficiency, but the company faces challenges with declining net sales and operating profit over the past five years, alongside a notable drop in net profit and cash flow.

Tasly Pharmaceutical Group Co., Ltd. has recently experienced an evaluation adjustment, reflecting a complex assessment of its performance and market position. Despite reporting positive quarterly financials, the company faces long-term growth challenges, including declining net sales and operating profit, alongside a cautious approach to shareholder returns.

Tasly Pharmaceutical Group Co., Ltd. has recently experienced an evaluation adjustment reflecting changes in its financial metrics. Key indicators include a P/E ratio of 20, a Price to Book Value of 1.72, and a dividend yield of 2.89%. The company faces challenges in long-term growth despite this revised assessment.

Tasly Pharmaceutical Group Co., Ltd. saw a significant increase in stock price on March 27, 2026, contrasting with the modest gain of the China Shanghai Composite. Despite recent positive trends, the company faces long-term challenges, including declining net sales and a substantial drop in net profit over the past five years.

Tasly Pharmaceutical Group Co., Ltd. faced a significant decline in stock value, dropping 4.45% on March 23, 2026. The company has experienced a 10.52% decrease over the past year, with net sales contracting at an annual rate of 9.48% and a notable drop in net profit and operating cash flow.